What is Leerink Partnrs’ Estimate for HIMS FY2024 Earnings?

Hims & Hers Health, Inc. (NYSE:HIMS) – Research analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Hims & Hers Health in a report issued on Tuesday, October 29th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $0.23 for the year, up from their prior forecast of $0.22. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s FY2027 earnings at $0.91 EPS.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter last year, the firm earned ($0.03) earnings per share. The firm’s quarterly revenue was up 51.8% compared to the same quarter last year.

Other analysts also recently issued research reports about the stock. TD Cowen lifted their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Truist Financial boosted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Finally, Piper Sandler reissued a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and an average target price of $20.21.

Hims & Hers Health Price Performance

Shares of HIMS opened at $18.85 on Thursday. The firm has a 50-day simple moving average of $17.94 and a two-hundred day simple moving average of $18.01. The stock has a market cap of $4.05 billion, a PE ratio of 235.56 and a beta of 1.06. Hims & Hers Health has a 1-year low of $5.76 and a 1-year high of $25.74.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC increased its holdings in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC increased its stake in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health during the second quarter worth about $111,000. Finally, Amalgamated Bank grew its holdings in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after buying an additional 2,354 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,334 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20. Following the sale, the insider now owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $551,777.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,334 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total value of $40,378.20. Following the completion of the sale, the insider now directly owns 164,475 shares of the company’s stock, valued at $2,845,417.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 858,665 shares of company stock valued at $15,148,890. 17.71% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.